VOLUME 5 (2014)
View Archive »
About The Cover
In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential. See Raffeiner et al.
|
|
Table of Contents
Editorial
|
| New targets for resistant prostate cancer |
|
https://doi.org/10.18632/oncotarget.2544
|
| 8816-8817 |
Reviews
|
| Axl as a mediator of cellular growth and survival |
|
https://doi.org/10.18632/oncotarget.2422
|
| 8818-8852 |
Priority Research Papers
|
| Hypoxiainducible factors enhance glutamate signaling in cancer cells |
|
https://doi.org/10.18632/oncotarget.2593
|
| 8853-8868 |
|
| In vivo quantification and perturbation of MycMax interactions and the impact on oncogenic potential |
|
https://doi.org/10.18632/oncotarget.2588
|
| 8869-8878 |
|
| Small molecule restoration of wildtype structure and function of mutant p53 using a novel zincmetallochaperone based mechanism |
|
https://doi.org/10.18632/oncotarget.2432
|
| 8879-8892 |
|
| MUC1C confers EMT and KRAS independence in mutant KRAS lung cancer cells |
|
https://doi.org/10.18632/oncotarget.2360
|
| 8893-8905 |
|
| The head and neck cancer cell oncogenome: A platform for the development of precision molecular therapies |
|
https://doi.org/10.18632/oncotarget.2417
|
| 8906-8923 |
|
| Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells |
|
https://doi.org/10.18632/oncotarget.2441
|
| 8924-8936 |
Clinical Research Papers
|
| Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials |
|
https://doi.org/10.18632/oncotarget.2339
|
| 8937-8946 |
|
| Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition |
|
https://doi.org/10.18632/oncotarget.2407
|
| 8947-8958 |
Research Papers
|
| The functional characterization of long noncoding RNA SPRY4IT1 in human melanoma cells |
|
https://doi.org/10.18632/oncotarget.1863
|
| 8959-8969 |
|
| A novel tumor suppressor function of Kindlin3 in solid cancer |
|
https://doi.org/10.18632/oncotarget.2125
|
| 8970-8985 |
|
| Glycogen synthase kinase3β inhibition depletes the population of prostate cancer stem/progenitorlike cells and attenuates metastatic growth |
|
https://doi.org/10.18632/oncotarget.1510
|
| 8986-8994 |
|
| The classspecific BCR tonic signal modulates lymphomagenesis in a cmyc deregulation transgenic model |
|
https://doi.org/10.18632/oncotarget.2297
|
| 8995-9006 |
|
| A novel calciumdependent mechanism of acquired resistance to IGF1 receptor inhibition in prostate cancer cells |
|
https://doi.org/10.18632/oncotarget.2346
|
| 9007-9021 |
|
| Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways |
|
https://doi.org/10.18632/oncotarget.2493
|
| 9022-9032 |
|
| The BCL2 inhibitor ABT199 significantly enhances imatinibinduced cell death in chronic myeloid leukemia progenitors |
|
https://doi.org/10.18632/oncotarget.1925
|
| 9033-9038 |
|
| Chemosensitization of solid tumors by inhibition of BclxL expression using DNAzyme |
|
https://doi.org/10.18632/oncotarget.1996
|
| 9039-9048 |
|
| Targeting tyrosinekinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer |
|
https://doi.org/10.18632/oncotarget.2022
|
| 9049-9064 |
|
| Gankyrin is a predictive and oncogenic factor in welldifferentiated and dedifferentiated liposarcoma |
|
https://doi.org/10.18632/oncotarget.2375
|
| 9065-9078 |
|
| Prolactin induces upregulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by crosstalk between ERα and STAT5 |
|
https://doi.org/10.18632/oncotarget.2376
|
| 9079-9091 |
|
| LGR5 promotes the proliferation and tumor formation of cervical cancer cells through the Wnt/βcatenin signaling pathway |
|
https://doi.org/10.18632/oncotarget.2377
|
| 9092-9105 |
|
| MicroRNA3395p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling |
|
https://doi.org/10.18632/oncotarget.2379
|
| 9106-9117 |
|
| Antirheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abldependent and independent mechanisms |
|
https://doi.org/10.18632/oncotarget.2361
|
| 9118-9132 |
|
| p70 S6 kinase drives ovarian cancer metastasis through multicellular spheroidperitoneum interaction and Pcadherin/β1 integrin signaling activation |
|
https://doi.org/10.18632/oncotarget.2362
|
| 9133-9149 |
|
| Crizotinib exhibits antitumor activity by targeting ALK signaling not cMET in pancreatic cancer |
|
https://doi.org/10.18632/oncotarget.2363
|
| 9150-9168 |
|
| Biphasic regulation of autophagy by miR96 in prostate cancer cells under hypoxia |
|
https://doi.org/10.18632/oncotarget.2396
|
| 9169-9182 |
|
| Binding of a Smad4/Ets1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemia |
|
https://doi.org/10.18632/oncotarget.2399
|
| 9183-9198 |
|
| Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways druggable mutations and mutated epitopes for targeted therapy |
|
https://doi.org/10.18632/oncotarget.2374
|
| 9199-9213 |
|
| Vav1 promotes lung cancer growth by instigating tumormicroenvironment crosstalk via growth factor secretion |
|
https://doi.org/10.18632/oncotarget.2400
|
| 9214-9226 |
|
| Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer |
|
https://doi.org/10.18632/oncotarget.2402
|
| 9227-9238 |
|
| Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOXanchored biotinylated Cetuximab |
|
https://doi.org/10.18632/oncotarget.2409
|
| 9239-9255 |
|
| Rpb3 promotes hepatocellular carcinoma through its Nterminus |
|
https://doi.org/10.18632/oncotarget.2389
|
| 9256-9268 |
|
| DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition |
|
https://doi.org/10.18632/oncotarget.2393
|
| 9269-9280 |
|
| Loss of Trop2 causes ErbB3 activation through a neuregulin1dependent mechanism in the mesenchymal subtype of HNSCC |
|
https://doi.org/10.18632/oncotarget.2423
|
| 9281-9294 |
|
| Combining targeted drugs to overcome and prevent resistance of solid cancers with some stemlike cell features |
|
https://doi.org/10.18632/oncotarget.2424
|
| 9295-9307 |
|
| Multidrug resistance protein 4/ ATP binding cassette transporter 4: a new potential therapeutic target for acute myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.2425
|
| 9308-9321 |
|
| P2Y2R activation by nucleotides released from the highly metastatic breast cancer cell contributes to premetastatic niche formation by mediating lysyl oxidase secretion collagen crosslinking and monocyte recruitment |
|
https://doi.org/10.18632/oncotarget.2427
|
| 9322-9334 |
|
| Androgen deprivation therapy sensitizes prostate cancer cells to Tcell killing through androgen receptor dependent modulation of the apoptotic pathway |
|
https://doi.org/10.18632/oncotarget.2429
|
| 9335-9348 |
|
| Transcriptional coactivator CBP upregulates hTERT expression and tumor growth and predicts poor prognosis in human lung cancers |
|
https://doi.org/10.18632/oncotarget.2430
|
| 9349-9361 |
|
| The fatty acid synthase inhibitor triclosan: repurposing an antimicrobial agent for targeting prostate cancer |
|
https://doi.org/10.18632/oncotarget.2433
|
| 9362-9381 |
|
| Transcriptional profiling of GBM invasion genes identifies effective inhibitors of the LIM kinaseCofilin pathway |
|
https://doi.org/10.18632/oncotarget.2412
|
| 9382-9395 |
|
| The DNA2 nuclease/helicase is an estrogendependent gene mutated in breast and ovarian cancers |
|
https://doi.org/10.18632/oncotarget.2414
|
| 9396-9409 |
|
| Overexpression of Collagen Triple Helix Repeat Containing 1 CTHRC1 is associated with tumour aggressiveness and poor prognosis in human nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.2421
|
| 9410-9424 |
|
| Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis |
|
https://doi.org/10.18632/oncotarget.2444
|
| 9425-9443 |
|
| miR5245p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2 |
|
https://doi.org/10.18632/oncotarget.2452
|
| 9444-9459 |
|
| GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer |
|
https://doi.org/10.18632/oncotarget.2455
|
| 9460-9471 |
|
| miR382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma |
|
https://doi.org/10.18632/oncotarget.2418
|
| 9472-9483 |
|
| What makes a blood cell based miRNA expression pattern disease specific A miRNome analysis of blood cell subsets in lung cancer patients and healthy controls |
|
https://doi.org/10.18632/oncotarget.2419
|
| 9484-9497 |
|
| TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer |
|
https://doi.org/10.18632/oncotarget.2411
|
| 9498-9513 |
|
| FOXF1 mediates mesenchymal stem cell fusioninduced reprogramming of lung cancer cells |
|
https://doi.org/10.18632/oncotarget.2413
|
| 9514-9529 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
